About: Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Creator	Chen, Zhu Qin, Cheng-Feng Zhao, Peng Wang, Fu-Sheng Chang, De Sharma, Lokesh Li, Bo-An Yang, Guang Xu, Zhe Zhang, Da-Wei Qin, En-Qiang Dong, Jing-Hui Chen, En-Qiang Dela Cruz, Charles Qin, Zhao, Peng, Cruz, Dela Dela, Charles Ba, Li Cf, Qin Chang, Peng Corresponding, Fu-Sheng Cs, Cruz Dela Cruz, Lokesh Dela, Chen Dong, Xiao-Hua Dw, Zhang Eq, Qin First, * Fs, Wang Hx, Liu Jh, Dong Li, Bo-Yu Li, De Li, Hong-Xia Liu, Bo-An Liu, Hong-Xia Lx, Xie Md, § Md&phd, Peng Peng, Xiao-Hua Qiang, En Qin, # Senior, Charles Sharma, Charles Sharma, En-Qiang Wang, Li-Xin Xh, Peng Xie, Li-Xin Xie, Zhu Xu, Guang Yang, Bo-Yu Zhang, Jing-Hui Zhao, Da-Wei
Source	Elsevier; Medline; PMC
abstract	Abstract Background The clinical management of COVID-19 is dependent on understanding the underlying factors that contribute to the disease severity. In the absence of effective antiviral therapies, other host immunomodulatory therapies such as targeting inflammatory response are currently being used without clear evidence of their effectiveness. As inflammation is an essential component of host antiviral mechanisms, therapies targeting inflammation may adversely affect viral clearance and disease outcome. Objective To understand whether the persistent presence of the virus is a key determinant in the disease severity during COVID-19 and to determine if the viral reactivation in some patients is associated with infectious viral particles. Methods The data for patients were available including the onset of the disease, duration of viral persistence, measurements of inflammatory markers such as IL-6 and CRP, chest imaging, disease symptoms, and their durations among others. Follow up tests were performed to determine if the viral negative status persists after their recovery. Results Our data show that patients with persistent viral presence (>16 days) have more severe disease outcomes including extensive lung involvement and requirement of respiratory support. Two patients who died of COVID-19 were virus-positive at the time of their death. Four patients demonstrated virus-positive status on the follow-up tests and these patient samples were sent to viral culture facility where virus culture could not be established. Conclusion These data suggest that viral persistence is the key determining factor of the disease severity. Therapies that may impair the viral clearance may impair the host recovery from the COVID-19.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1016/j.jaip.2020.06.015
bibo:pmid	32574840
has license	els-covid
sha1sum (hex)	2408e2d5deccfc89321847a78431bc21e249a35d
schema:url	https://doi.org/10.1016/j.jaip.2020.06.015
resource representing a document's title	Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
has PubMed Central identifier	PMC7305869
has PubMed identifier	32574840
schema:publication	J Allergy Clin Immunol Pract
resource representing a document's body	covid:2408e2d5deccfc89321847a78431bc21e249a35d#body_text
is schema:about of	named entity 'mechanisms' named entity 'Presence' named entity 'COVID-19' named entity 'DEPENDENT' named entity 'EVIDENCE OF' named entity 'host' named entity 'antiviral' named entity 'antiviral' named entity 'dependent' named entity 'immunomodulatory' named entity 'antiviral' named entity 'COVID' named entity 'long-term' named entity 'inflammatory response' named entity 'long-term' named entity 'D-dimer' named entity 'SARS-CoV-2' named entity 'chest imaging' named entity 'inflammatory response' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'anti-inflammatory' named entity 'CD8+' named entity 'Lymphocyte' named entity 'Vero' named entity 'inflammation' named entity 'pathology'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software